A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: guarantee (67), certify (28), warrant (16)

BRC Research-imaging-proposal-form_v1 FINAL 10.12.2024

Description
BRC Research Imaging Proposal form The BRC Research Imaging Proposal form should be completed by the chief/principal investigator of any new research study r
Url
/Media/Southampton-Clinical-Research/Downloads/BRC-Research-imaging-proposal-form-v1-FINAL-10.12.2024.docx

AmB-Axicabtagene ciloleucel-Cyclophosphamide (500)-Fludarabine (30)

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Large B-cell Lymphoma (LBL) AmB- AXICEL – CY
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Axicabtagene-ciloleucel-Cyclophosphamide-500-Fludarabine-30.pdf

EC-DPH IV (Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab IV)

Description
Please refer to the most up to date Bluteq eligibility criteria for pertuzumab and trastuzumab before prescribing.
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-DPH-IV-Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab-IV.pdf

AmB - Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Mantle Cell lymphoma (MCL) AmB – BREXUCEL – CY
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Brexucel-Cyclophosphamide-500-Fludarabine-30-Ver-1.pdf

AmB LEAM (split)-Lomustine-Cytarabine-Etoposide-Melphalan

Description
Chemotherapy Protocol LYMPHOMA LOMUSTINE-CYTARABINE-ETOPOSIDE (split)-MELPHALAN (LEAM) Ambulatory Regimen This regimen is for AMBULATORY CARE pathw
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LEAM-split-Lomustine-Cytarabine-Etoposide-Melphalan.pdf

STH74 V4 Quantiferon guidelines

Description
UHSNFT Microbiology STH74/04-20 QuantiFERON® Guidelines STH74/04-20 QuantiFERON® Guidelines Summary 1 Princ
Url
/Media/UHS-website-2019/Docs/Services/Pathology/STH74-V4-Quantiferon-guidelines.doc

ACC_postdoc_JD_031122

Description
Job Description and Person Specification Last updated: November 2022 JOB DESCRIPTION Post title: Senior Research Fellow Academic Unit/Service:
Url
/Media/Southampton-Clinical-Research/Downloads/ACC-postdoc-JD-031122.docx

EC-DPH SC (Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab+Trastuzumab SC)

Description
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-DOCETAXEL-PERTUZUMAB / TRASTUZUMAB SC (EC-DPH SC) Regimen  Breast Cancer – Cyc
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-DPH-SC-Cyclophosphamide-Epirubicin-Docetaxel-PertuzumabTrastuzumab-SC.pdf

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description
Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezom
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

CH001 SOP protocol verification

Description
Standard Operating Procedure Production of Chemotherapy Protocols (SOP:CH001) 1. Objective 1.1 The purpose of this standard oper
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Validation/CH001SOP-protocol-verification.pdf
181 to 190 of 1000
Previous … 17 18 19 20 21 … Next